ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
about
Immune checkpoint inhibitors: therapeutic advances in melanomaT-cell receptor gene therapy--ready to go viral?Uveal melanoma: epidemiology, etiology, and treatment of primary disease.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions.New clinical advances in immunotherapy for the treatment of solid tumours.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.Building proteomic tool boxes to monitor MHC class I and class II peptides.Current progress in innovative engineered antibodies.The making of bispecific antibodiesPolyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.Bispecific antibodies: design, therapy, perspectives.Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.
P2860
Q26775591-2FD7DF43-FF39-4DAC-A7B2-15DED85C1F0AQ28081611-906DA51B-ED3B-412A-9833-2C7ACA3584D9Q30235934-669C616C-D091-4176-8E73-46CA6557CC8BQ34000700-1CF0D517-A1D0-4064-A1D8-C6B12BCBBE9EQ37499526-ADA8B0DA-305E-41AD-8EF3-28E4E2ACB2C0Q37642191-311D5AA5-3500-4648-A876-9CD279CF8C22Q38335303-D07B92D4-AF0F-4CE1-B531-62315386EA0CQ38397279-42471B1B-4188-4103-B51E-8E07B69824F8Q38808823-817203B2-6CC4-404C-AA33-3A69A5C83D85Q38838649-DA6B6804-A68A-41E0-B458-002B8C5D6EF9Q39032610-9D0D9190-DAA7-442D-99EC-51F4DAC2DBEAQ40077818-E15AF66B-CEB0-4EA2-B456-9DDE1E6C108AQ42323236-61FA8F70-9934-4023-95D2-2124923300F7Q42371124-ECB74D45-F5E9-4B14-A1D3-29474D481101Q49195146-4AAA966A-9B1A-4FE1-B4D7-CD767B9966E1Q55455666-363C25AD-7B06-4626-BF33-E5F5777A7D73
P2860
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@en
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@nl
type
label
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@en
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@nl
prefLabel
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@en
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@nl
P2093
P2860
P1476
ImmTAC-redirected tumour cell ...... esentation by dendritic cells.
@en
P2093
Bent K Jakobsen
Giovanna Bossi
Joanne Oates
Namir J Hassan
Sandrine Buisson
P2860
P2888
P304
P356
10.1007/S00262-014-1525-Z
P577
2014-02-15T00:00:00Z